Robert F. Williamson III Buys 6,266 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III purchased 6,266 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $3.64 per share, for a total transaction of $22,808.24. Following the purchase, the director now owns 430,058 shares in the company, valued at $1,565,411.12. The trade was a 1.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Perspective Therapeutics Stock Up 5.8 %

Shares of NYSE CATX opened at $4.36 on Friday. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The business’s 50 day moving average is $10.60 and its two-hundred day moving average is $12.27.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million during the quarter. On average, equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after acquiring an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Perspective Therapeutics during the first quarter valued at approximately $15,511,000. FMR LLC raised its stake in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. State Street Corp lifted its position in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Finally, Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics during the third quarter worth $21,390,000. Institutional investors own 54.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Royal Bank of Canada reduced their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, November 25th. Finally, UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Perspective Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.